JP2018508469A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018508469A5 JP2018508469A5 JP2017533956A JP2017533956A JP2018508469A5 JP 2018508469 A5 JP2018508469 A5 JP 2018508469A5 JP 2017533956 A JP2017533956 A JP 2017533956A JP 2017533956 A JP2017533956 A JP 2017533956A JP 2018508469 A5 JP2018508469 A5 JP 2018508469A5
- Authority
- JP
- Japan
- Prior art keywords
- antagonist
- patient
- expression level
- egfr
- fgfr3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 36
- 230000014509 gene expression Effects 0.000 claims 28
- 108090000623 proteins and genes Proteins 0.000 claims 24
- 239000005557 antagonist Substances 0.000 claims 22
- 239000000523 sample Substances 0.000 claims 19
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 claims 18
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 claims 18
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims 17
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 claims 17
- 239000003814 drug Substances 0.000 claims 15
- 206010005003 Bladder cancer Diseases 0.000 claims 13
- 229940122558 EGFR antagonist Drugs 0.000 claims 13
- 239000002246 antineoplastic agent Substances 0.000 claims 11
- 239000003795 chemical substances by application Substances 0.000 claims 10
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 9
- 201000005112 urinary bladder cancer Diseases 0.000 claims 9
- 239000012634 fragment Substances 0.000 claims 8
- 238000011319 anticancer therapy Methods 0.000 claims 7
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 7
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 7
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 7
- -1 BCL2B Proteins 0.000 claims 5
- 238000004393 prognosis Methods 0.000 claims 5
- 230000004083 survival effect Effects 0.000 claims 5
- 229940124597 therapeutic agent Drugs 0.000 claims 5
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 4
- 229940127089 cytotoxic agent Drugs 0.000 claims 4
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 230000003387 muscular Effects 0.000 claims 3
- 150000003384 small molecules Chemical class 0.000 claims 3
- 238000011282 treatment Methods 0.000 claims 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims 2
- 241001467552 Mycobacterium bovis BCG Species 0.000 claims 2
- 229940034982 antineoplastic agent Drugs 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims 2
- 229960001433 erlotinib Drugs 0.000 claims 2
- 238000003364 immunohistochemistry Methods 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 239000013610 patient sample Substances 0.000 claims 2
- 238000003752 polymerase chain reaction Methods 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 230000003439 radiotherapeutic effect Effects 0.000 claims 2
- 229940120982 tarceva Drugs 0.000 claims 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical group 0.000 claims 2
- 102100026802 72 kDa type IV collagenase Human genes 0.000 claims 1
- 102000006311 Cyclin D1 Human genes 0.000 claims 1
- 108010058546 Cyclin D1 Proteins 0.000 claims 1
- 108010016788 Cyclin-Dependent Kinase Inhibitor p21 Proteins 0.000 claims 1
- 102100033270 Cyclin-dependent kinase inhibitor 1 Human genes 0.000 claims 1
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 claims 1
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 claims 1
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 claims 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims 1
- 102100037665 Fibroblast growth factor 9 Human genes 0.000 claims 1
- 102100021066 Fibroblast growth factor receptor substrate 2 Human genes 0.000 claims 1
- 102100021064 Fibroblast growth factor receptor substrate 3 Human genes 0.000 claims 1
- 102100031561 Hamartin Human genes 0.000 claims 1
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 claims 1
- 101001027380 Homo sapiens Fibroblast growth factor 9 Proteins 0.000 claims 1
- 101000818410 Homo sapiens Fibroblast growth factor receptor substrate 2 Proteins 0.000 claims 1
- 101000818396 Homo sapiens Fibroblast growth factor receptor substrate 3 Proteins 0.000 claims 1
- 101000795643 Homo sapiens Hamartin Proteins 0.000 claims 1
- 101001120056 Homo sapiens Phosphatidylinositol 3-kinase regulatory subunit alpha Proteins 0.000 claims 1
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 claims 1
- 101000595741 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform Proteins 0.000 claims 1
- 101000779418 Homo sapiens RAC-alpha serine/threonine-protein kinase Proteins 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 101000807561 Homo sapiens Tyrosine-protein kinase receptor UFO Proteins 0.000 claims 1
- 101000785626 Homo sapiens Zinc finger E-box-binding homeobox 1 Proteins 0.000 claims 1
- 101000723833 Homo sapiens Zinc finger E-box-binding homeobox 2 Proteins 0.000 claims 1
- 101000702691 Homo sapiens Zinc finger protein SNAI1 Proteins 0.000 claims 1
- 101000633054 Homo sapiens Zinc finger protein SNAI2 Proteins 0.000 claims 1
- 238000002944 PCR assay Methods 0.000 claims 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 claims 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 claims 1
- 102100026169 Phosphatidylinositol 3-kinase regulatory subunit alpha Human genes 0.000 claims 1
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 claims 1
- 102100036061 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform Human genes 0.000 claims 1
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 1
- 102100027881 Tumor protein 63 Human genes 0.000 claims 1
- 101710140697 Tumor protein 63 Proteins 0.000 claims 1
- 102100037236 Tyrosine-protein kinase receptor UFO Human genes 0.000 claims 1
- 102100026457 Zinc finger E-box-binding homeobox 1 Human genes 0.000 claims 1
- 102100028458 Zinc finger E-box-binding homeobox 2 Human genes 0.000 claims 1
- 102100030917 Zinc finger protein SNAI1 Human genes 0.000 claims 1
- 102100029570 Zinc finger protein SNAI2 Human genes 0.000 claims 1
- 229940124650 anti-cancer therapies Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 239000012188 paraffin wax Substances 0.000 claims 1
- 238000010837 poor prognosis Methods 0.000 claims 1
- 238000003753 real-time PCR Methods 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021099307A JP2021169451A (ja) | 2014-12-24 | 2021-06-15 | 膀胱癌の治療、診断、及び予後判定方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462096741P | 2014-12-24 | 2014-12-24 | |
| US62/096,741 | 2014-12-24 | ||
| PCT/US2015/000237 WO2016105503A1 (en) | 2014-12-24 | 2015-12-23 | Therapeutic, diagnostic and prognostic methods for cancer of the bladder |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021099307A Division JP2021169451A (ja) | 2014-12-24 | 2021-06-15 | 膀胱癌の治療、診断、及び予後判定方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018508469A JP2018508469A (ja) | 2018-03-29 |
| JP2018508469A5 true JP2018508469A5 (enExample) | 2019-01-31 |
| JP6900314B2 JP6900314B2 (ja) | 2021-07-07 |
Family
ID=55275150
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017533956A Active JP6900314B2 (ja) | 2014-12-24 | 2015-12-23 | 膀胱癌の治療、診断、及び予後判定方法 |
| JP2021099307A Pending JP2021169451A (ja) | 2014-12-24 | 2021-06-15 | 膀胱癌の治療、診断、及び予後判定方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021099307A Pending JP2021169451A (ja) | 2014-12-24 | 2021-06-15 | 膀胱癌の治療、診断、及び予後判定方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20170306418A1 (enExample) |
| EP (2) | EP3237638B1 (enExample) |
| JP (2) | JP6900314B2 (enExample) |
| KR (1) | KR20170095893A (enExample) |
| CN (1) | CN107223163A (enExample) |
| AU (1) | AU2015371312B2 (enExample) |
| CA (1) | CA2969830A1 (enExample) |
| HK (1) | HK1244847A1 (enExample) |
| IL (1) | IL252796B (enExample) |
| MX (1) | MX394474B (enExample) |
| MY (1) | MY188938A (enExample) |
| RU (1) | RU2739942C2 (enExample) |
| SG (1) | SG11201704852SA (enExample) |
| WO (1) | WO2016105503A1 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101525754B1 (ko) | 2007-03-28 | 2015-06-09 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 스티칭된 폴리펩티드 |
| EP4279513A3 (en) | 2010-11-30 | 2024-02-28 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
| TW201806968A (zh) | 2011-10-18 | 2018-03-01 | 艾利倫治療公司 | 擬肽巨環化合物 |
| CA2864120A1 (en) | 2012-02-15 | 2013-08-22 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
| KR20150082307A (ko) | 2012-11-01 | 2015-07-15 | 에일러론 테라퓨틱스 인코포레이티드 | 이치환 아미노산 및 이의 제조 및 사용 방법 |
| MX2017003797A (es) | 2014-09-24 | 2017-06-15 | Aileron Therapeutics Inc | Macrociclos peptidomimeticos y usos de los mismos. |
| SG10201902598VA (en) | 2014-09-24 | 2019-04-29 | Aileron Therapeutics Inc | Peptidomimetic macrocycles and formulations thereof |
| MX2017007656A (es) * | 2014-12-11 | 2017-10-11 | Bayer Pharma AG | Uso de los inhibidores de pan fgfr y metodo para identificacion de pacientes con cancer elegibles para el tratamiento con un inhibidor de pan fgfr. |
| US10253067B2 (en) | 2015-03-20 | 2019-04-09 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| US10208024B2 (en) | 2015-10-23 | 2019-02-19 | Array Biopharma Inc. | 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases |
| US20180165599A1 (en) * | 2016-12-12 | 2018-06-14 | Business Objects Software Ltd. | Predictive model integration |
| CA3075743C (en) * | 2017-09-14 | 2023-02-28 | Siemens Healthcare Diagnostics Inc. | Adhesive-polymer containing membranes for in vitro diagnostic devices |
| CN110115758B (zh) * | 2018-02-05 | 2021-05-11 | 中山大学 | Pik3ip1蛋白在调节t细胞反应和制备抗肿瘤药物中的应用 |
| CN108676884A (zh) * | 2018-06-04 | 2018-10-19 | 海口市人民医院（中南大学湘雅医学院附属海口医院） | 一种用于预测膀胱癌的肿瘤标志物 |
| CN112955747A (zh) * | 2018-09-19 | 2021-06-11 | 豪夫迈·罗氏有限公司 | 膀胱癌的治疗和诊断方法 |
| CN111289748A (zh) * | 2018-12-08 | 2020-06-16 | 惠州市中大惠亚医院 | ErbB3蛋白在制备膀胱癌无创诊断产品中的应用 |
| EP3898626A1 (en) | 2018-12-19 | 2021-10-27 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases |
| JP2022515197A (ja) | 2018-12-19 | 2022-02-17 | アレイ バイオファーマ インコーポレイテッド | がんを治療するためのｆｇｆｒ阻害剤としての７－（（３，５－ジメトキシフェニル）アミノ）キノキサリン誘導体 |
| WO2020208260A1 (en) * | 2019-04-12 | 2020-10-15 | Stratifyer Molecular Pathology Gmbh | Method of classifying a sample based on determination of fgfr |
| CN110055331B (zh) * | 2019-05-10 | 2023-05-02 | 人和未来生物科技（长沙）有限公司 | 一种用于膀胱癌辅助诊断或筛查的试剂盒及其应用 |
| EP3998083A4 (en) * | 2019-07-12 | 2023-08-23 | Chugai Seiyaku Kabushiki Kaisha | Anti-mutation type fgfr3 antibody and use therefor |
| WO2021138391A1 (en) | 2019-12-30 | 2021-07-08 | Tyra Biosciences, Inc. | Indazole compounds |
| WO2021138392A1 (en) | 2019-12-30 | 2021-07-08 | Tyra Biosciences, Inc. | Aminopyrimidine compounds |
| CN111269983A (zh) * | 2020-02-21 | 2020-06-12 | 深圳市众循精准医学研究院 | 一种膀胱癌基因扩增的fish检测方法、探针及试剂盒 |
| WO2021189082A1 (en) * | 2020-03-18 | 2021-09-23 | The Regents Of The University Of California | Risk-stratification of meningioma patients |
| CN111679076A (zh) * | 2020-06-15 | 2020-09-18 | 吉林医药学院 | 一种用于检测cyclinD1和BCL-2抗体的检测试剂盒 |
| WO2022006596A1 (en) * | 2020-06-30 | 2022-01-06 | Northwestern University | A single patient classifier for t1 high grade bladder cancer |
| GB2597332A (en) * | 2020-07-20 | 2022-01-26 | Institute Of Cancer Res | Prognostic and treatment response predictive method |
| CA3205986A1 (en) | 2020-12-30 | 2022-07-07 | Tyra Biosciences, Inc. | Indazole compounds as kinase inhibitors |
| WO2022174234A2 (en) * | 2021-02-10 | 2022-08-18 | Foundation Medicine, Inc. | Biomarkers for cancer treatment |
| EP4297873A1 (en) | 2021-02-26 | 2024-01-03 | Tyra Biosciences, Inc. | Aminopyrimidine compounds and methods of their use |
| JP2023023327A (ja) * | 2021-08-05 | 2023-02-16 | 国立大学法人大阪大学 | 腫瘍のサブタイプ決定方法及びその応用、並びにサブタイプ決定のための方法 |
| IT202200001817A1 (it) | 2022-02-02 | 2023-08-02 | Aizoon S R L | Procedimento per la prognosi di una malattia in seguito ad un trattamento terapeutico, relativo sistema e prodotto informatico |
| IT202200005861A1 (it) | 2022-03-24 | 2023-09-24 | Aizoon S R L | Procedimento per stimare una variabile di interesse associata ad una data malattia in funzione di una pluralità di diversi dati omici, relativo dispositivo e prodotto informatico |
| CN115343474B (zh) * | 2022-06-27 | 2024-12-27 | 陕西佰美基因股份有限公司 | Ckap4蛋白的应用、产品、表达干扰试剂及预后模型构建方法 |
| TW202416961A (zh) | 2022-06-29 | 2024-05-01 | 美商泰拉生物科學公司 | 吲唑化合物 |
| EP4547670A1 (en) | 2022-06-29 | 2025-05-07 | Tyra Biosciences, Inc. | Polymorphic compounds and uses thereof |
| US20240028964A1 (en) | 2022-07-25 | 2024-01-25 | Aizoon S.r.l. | Method for providing a clinical decision support, corresponding system for providing a clinical decision support, and computer program product |
| WO2024138112A1 (en) | 2022-12-22 | 2024-06-27 | Tyra Biosciences, Inc. | Indazole compounds |
| TW202535368A (zh) | 2023-12-15 | 2025-09-16 | 美商泰拉生物科學公司 | 吲唑化合物 |
| WO2025222097A1 (en) | 2024-04-19 | 2025-10-23 | Tyra Biosciences, Inc. | Indazole-based protac degraders and their anticancer activity |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4018653A (en) | 1971-10-29 | 1977-04-19 | U.S. Packaging Corporation | Instrument for the detection of Neisseria gonorrhoeae without culture |
| US4016043A (en) | 1975-09-04 | 1977-04-05 | Akzona Incorporated | Enzymatic immunological method for the determination of antigens and antibodies |
| US4424279A (en) | 1982-08-12 | 1984-01-03 | Quidel | Rapid plunger immunoassay method and apparatus |
| US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
| US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
| US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
| US5527676A (en) | 1989-03-29 | 1996-06-18 | The Johns Hopkins University | Detection of loss of the wild-type P53 gene and kits therefor |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| EP0584222B1 (en) | 1991-05-10 | 1997-10-08 | Rhone-Poulenc Rorer International (Holdings) Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
| NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| EP0646178A1 (en) | 1992-06-04 | 1995-04-05 | The Regents Of The University Of California | expression cassette with regularoty regions functional in the mammmlian host |
| EP0672035A1 (en) | 1993-10-01 | 1995-09-20 | Novartis AG | Pyrimidineamine derivatives and processes for the preparation thereof |
| US5656643A (en) | 1993-11-08 | 1997-08-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| WO1995024190A2 (en) | 1994-03-07 | 1995-09-14 | Sugen, Inc. | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
| ES2109796T3 (es) | 1994-05-03 | 1998-01-16 | Ciba Geigy Ag | Derivados de pirrolopirimidilo con efecto antiproliferante. |
| US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
| US5910486A (en) | 1994-09-06 | 1999-06-08 | Uab Research Foundation | Methods for modulating protein function in cells using, intracellular antibody homologues |
| CA2216796C (en) | 1995-03-30 | 2003-09-02 | Pfizer Inc. | Quinazoline derivatives |
| JP4249804B2 (ja) | 1995-04-03 | 2009-04-08 | ノバルティス・アクチエンゲゼルシャフト | ピラゾール誘導体およびその製造法 |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| US5650415A (en) | 1995-06-07 | 1997-07-22 | Sugen, Inc. | Quinoline compounds |
| KR100437582B1 (ko) | 1995-07-06 | 2004-12-17 | 노파르티스 아게 | 피롤로피리미딘및그들의제조방법 |
| DK9500262U4 (da) | 1995-07-07 | 1996-10-07 | Bonus Energy As | Bundramme til vindmøllehus samt vindmølle omfattende samme |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| AR004010A1 (es) | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | Compuestos heterociclicos |
| GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| ES2177925T3 (es) | 1996-01-23 | 2002-12-16 | Novartis Ag | Pirrolopirimidinas y procedimientos para su preparacion. |
| JP3406763B2 (ja) | 1996-01-30 | 2003-05-12 | 東レ・ダウコーニング・シリコーン株式会社 | シリコーンゴム組成物 |
| GB9603097D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline compounds |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| DE19608588A1 (de) | 1996-03-06 | 1997-09-11 | Thomae Gmbh Dr K | Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| DE19629652A1 (de) | 1996-03-06 | 1998-01-29 | Thomae Gmbh Dr K | 4-Amino-pyrimidin-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| ES2203793T3 (es) | 1996-03-15 | 2004-04-16 | Novartis Ag | N-7-heterociclil-pirrolo(2,3-d)pirimidinas y su empleo. |
| EA001595B1 (ru) | 1996-04-12 | 2001-06-25 | Варнер-Ламберт Компани | Необратимые ингибиторы тирозинкиназ |
| GB9607729D0 (en) | 1996-04-13 | 1996-06-19 | Zeneca Ltd | Quinazoline derivatives |
| EP0907642B1 (en) | 1996-06-24 | 2005-11-02 | Pfizer Inc. | Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases |
| ID19430A (id) | 1996-07-13 | 1998-07-09 | Glaxo Group Ltd | Senyawa senyawa heterosiklik |
| HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
| AR007857A1 (es) | 1996-07-13 | 1999-11-24 | Glaxo Group Ltd | Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen. |
| DE69738468T2 (de) | 1996-08-23 | 2009-01-08 | Novartis Ag | Substituierte pyrrolopyrimidine und verfahren zu ihrer herstellung |
| AU4779897A (en) | 1996-10-02 | 1998-04-24 | Novartis Ag | Fused pyrazole derivatives and processes for their preparation |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| WO1998014450A1 (en) | 1996-10-02 | 1998-04-09 | Novartis Ag | Pyrimidine derivatives and processes for the preparation thereof |
| EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
| GB9621757D0 (en) | 1996-10-18 | 1996-12-11 | Ciba Geigy Ag | Phenyl-substituted bicyclic heterocyclyl derivatives and their use |
| ES2301194T3 (es) | 1997-02-05 | 2008-06-16 | Warner-Lambert Company Llc | Pirido 2,3-d pirimidinas y 4-aminopirimidinas como inhibidores de la proliferacion celular. |
| AU8689298A (en) | 1997-08-05 | 1999-03-01 | Sugen, Inc. | Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors |
| GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| UA74803C2 (uk) | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування |
| US6291496B1 (en) * | 1999-12-27 | 2001-09-18 | Andrew J. Dannenberg | Treating cancers associated with overexpression of class I family of receptor tyrosine kinases |
| WO2001075166A2 (en) | 2000-03-31 | 2001-10-11 | Genentech, Inc. | Compositions and methods for detecting and quantifying gene expression |
| US6500633B1 (en) * | 2000-04-26 | 2002-12-31 | Atairgin Technologies, Inc. | Method of detecting carcinomas |
| EP2325205A3 (en) | 2000-12-28 | 2011-10-12 | Altus Pharmaceuticals Inc. | Crystals of whole antibodies and fragments thereof and methods for making and using them |
| US20060008823A1 (en) | 2004-05-12 | 2006-01-12 | Kemp Jennifer T | DNA profiling and SNP detection utilizing microarrays |
| US7932026B2 (en) * | 2004-06-04 | 2011-04-26 | Genentech, Inc. | EGFR mutations |
| SG174904A1 (en) | 2009-03-25 | 2011-11-28 | Genentech Inc | Anti-fgfr3 antibodies and methods using same |
| US20130059303A1 (en) * | 2011-09-06 | 2013-03-07 | Francois Radvanyi | Cdkn2a as a prognostic marker in bladder cancer |
| RU2015102194A (ru) | 2012-07-27 | 2016-09-20 | Дженентек, Инк. | Способы лечения связанных с fgfr3 состояний |
| EP2912467A4 (en) * | 2012-10-26 | 2016-04-20 | Univ Queensland | METHOD FOR CLASSIFYING TUMORS AND USE THEREOF |
| WO2014135655A1 (en) * | 2013-03-06 | 2014-09-12 | Institut Curie | Compositions and methods for treating muscle-invasive bladder cancer |
| NZ630213A (en) * | 2013-03-14 | 2017-05-26 | Abraxis Bioscience Llc | Methods of treating bladder cancer |
-
2015
- 2015-12-23 RU RU2017125053A patent/RU2739942C2/ru active
- 2015-12-23 SG SG11201704852SA patent/SG11201704852SA/en unknown
- 2015-12-23 CN CN201580075170.9A patent/CN107223163A/zh active Pending
- 2015-12-23 MY MYPI2017000931A patent/MY188938A/en unknown
- 2015-12-23 KR KR1020177017321A patent/KR20170095893A/ko not_active Ceased
- 2015-12-23 JP JP2017533956A patent/JP6900314B2/ja active Active
- 2015-12-23 WO PCT/US2015/000237 patent/WO2016105503A1/en not_active Ceased
- 2015-12-23 EP EP15831090.4A patent/EP3237638B1/en active Active
- 2015-12-23 AU AU2015371312A patent/AU2015371312B2/en not_active Ceased
- 2015-12-23 HK HK18104105.4A patent/HK1244847A1/zh unknown
- 2015-12-23 EP EP19212435.2A patent/EP3699290A1/en not_active Withdrawn
- 2015-12-23 MX MX2017008421A patent/MX394474B/es unknown
- 2015-12-23 CA CA2969830A patent/CA2969830A1/en active Pending
-
2017
- 2017-06-08 IL IL252796A patent/IL252796B/en unknown
- 2017-06-21 US US15/628,775 patent/US20170306418A1/en not_active Abandoned
-
2021
- 2021-06-15 JP JP2021099307A patent/JP2021169451A/ja active Pending
-
2022
- 2022-05-12 US US17/743,230 patent/US20220267864A1/en not_active Abandoned
-
2023
- 2023-01-20 US US18/157,597 patent/US20230220491A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018508469A5 (enExample) | ||
| Zuo et al. | AXL/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma | |
| Jhaveri et al. | Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q | |
| RU2017125053A (ru) | Терапевтические, диагностические и прогностические способы для рака мочевого пузыря | |
| Yoshimura et al. | EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib | |
| McArthur et al. | Targeting oncogenic drivers and the immune system in melanoma | |
| Jimeno et al. | A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer | |
| Wirth et al. | Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck | |
| Li et al. | The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere | |
| Spagnolo et al. | Upcoming strategies for the treatment of metastatic melanoma | |
| Seront et al. | Phase II study of dual phosphoinositol‐3‐kinase (PI 3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ 235 in patients with locally advanced or metastatic transitional cell carcinoma | |
| Gandara et al. | A phase 1/1b study evaluating trametinib plus docetaxel or pemetrexed in patients with advanced non–small cell lung cancer | |
| Brunner et al. | Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung | |
| Park et al. | Survival benefit of pemetrexed in lung adenocarcinoma patients with anaplastic lymphoma kinase gene rearrangements | |
| CN112888458A (zh) | Cldn18的抗体和化疗药物的联合治疗 | |
| Zhang et al. | The new concepts on overcoming drug resistance in lung cancer | |
| Long et al. | Evaluation of KRAS inhibitor-directed therapies for pancreatic cancer treatment | |
| JP2018513155A5 (enExample) | ||
| Park et al. | Predictive factors for the efficacy of cetuximab plus chemotherapy as salvage therapy in metastatic gastric cancer patients | |
| Guigay et al. | Long-term response in patient with recurrent oropharyngeal carcinoma treated with cetuximab, docetaxel and cisplatin (TPEx) as first-line treatment followed by cetuximab maintenance | |
| Yang et al. | Enhanced antitumor effects of radiotherapy combined local nimustine delivery rendezvousing with oral temozolomide chemotherapy in glioblastoma patients | |
| US20170079979A1 (en) | Therapy for solid tumors | |
| Nelson et al. | Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple‐negative breast cancer | |
| RU2715551C1 (ru) | Способ прогнозирования эффективности неоадъювантной химиотерапии при тройном негативном раке молочной железы | |
| Kim | Personalized therapy in oncology: melanoma as a paradigm for molecular-targeted treatment approaches |